JP2019531293A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019531293A5 JP2019531293A5 JP2019515467A JP2019515467A JP2019531293A5 JP 2019531293 A5 JP2019531293 A5 JP 2019531293A5 JP 2019515467 A JP2019515467 A JP 2019515467A JP 2019515467 A JP2019515467 A JP 2019515467A JP 2019531293 A5 JP2019531293 A5 JP 2019531293A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- peptide consisting
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 35
- 125000003275 alpha amino acid group Chemical group 0.000 claims 28
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 7
- 208000035473 Communicable disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 230000003463 hyperproliferative effect Effects 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 4
- 206010040047 Sepsis Diseases 0.000 claims 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 229940022399 cancer vaccine Drugs 0.000 claims 1
- 238000009566 cancer vaccine Methods 0.000 claims 1
- 238000002659 cell therapy Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 239000012646 vaccine adjuvant Substances 0.000 claims 1
- 229940124931 vaccine adjuvant Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662395195P | 2016-09-15 | 2016-09-15 | |
| US62/395,195 | 2016-09-15 | ||
| PCT/US2017/051697 WO2018053218A1 (en) | 2016-09-15 | 2017-09-15 | Pd-1 peptide inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019531293A JP2019531293A (ja) | 2019-10-31 |
| JP2019531293A5 true JP2019531293A5 (OSRAM) | 2020-11-05 |
| JP6928083B2 JP6928083B2 (ja) | 2021-09-01 |
Family
ID=60009711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019515467A Active JP6928083B2 (ja) | 2016-09-15 | 2017-09-15 | Ｐｄ−１ペプチド阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US10098950B2 (OSRAM) |
| EP (2) | EP3795167B1 (OSRAM) |
| JP (1) | JP6928083B2 (OSRAM) |
| AU (1) | AU2017325866B2 (OSRAM) |
| CA (1) | CA3036251A1 (OSRAM) |
| DK (2) | DK3512536T3 (OSRAM) |
| WO (1) | WO2018053218A1 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3512536T3 (da) | 2016-09-15 | 2020-11-23 | Leidos Inc | Pd-1-peptidinhibitorer |
| US10799555B2 (en) | 2016-09-15 | 2020-10-13 | Leidos, Inc. | PD-1 peptide inhibitors |
| ES3041991T3 (en) | 2017-05-25 | 2025-11-17 | Leidos Inc | Pd-1 and ctla-4 dual inhibitor peptides |
| AU2018410849B2 (en) * | 2018-02-27 | 2025-02-27 | Leidos, Inc. | PD-1 peptide inhibitors |
| CN109265533B (zh) * | 2018-10-30 | 2020-11-17 | 广东赛尔生物科技有限公司 | 一种改进的能与pd-1特异性结合的肿瘤抑制肽及其用途 |
| US11338040B2 (en) | 2020-06-04 | 2022-05-24 | Leidos, Inc. | Immunomodulatory compounds |
| CA3198203A1 (en) * | 2020-10-12 | 2022-04-21 | Leidos, Inc. | Immunomodulatory peptides |
| AU2022215566A1 (en) | 2021-02-02 | 2023-08-17 | Geovax, Inc. | Viral constructs for use in enhancing t-cell priming during vaccination |
| CN113336824A (zh) * | 2021-04-30 | 2021-09-03 | 重庆理工大学 | 一种多肽在作为pd-1/pd-l1蛋白-蛋白相互作用(ppi)调节剂中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2324650A1 (en) | 1998-05-06 | 1999-11-11 | Paul F. Russell | Introduction of naked dna or rna encoding non-human vertebrate peptide hormones or cytokines into a non-human vertebrate |
| CA2790134A1 (en) | 2010-02-16 | 2011-08-25 | Valorisation-Recherche, Limited Partnership | Pd-1 modulation and uses thereof for modulating hiv replication |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
| WO2012168944A1 (en) | 2011-06-08 | 2012-12-13 | Aurigene Discovery Technologies Limited | Therapeutic compounds for immunomodulation |
| CN104159911A (zh) | 2012-03-07 | 2014-11-19 | 奥瑞基尼探索技术有限公司 | 作为免疫调节剂的模拟肽化合物 |
| RU2014143443A (ru) | 2012-03-29 | 2016-05-20 | Ориджин Дискавери Текнолоджиз Лимитед | Иммуномодулирующие циклические соединения |
| ES2649180T3 (es) | 2013-02-22 | 2018-01-10 | Curevac Ag | Combinación de vacunación e inhibición de la ruta PD-1 |
| CA2955676A1 (en) | 2014-08-25 | 2016-03-03 | Pfizer Inc. | Combination of a pd-1 antagonist and an alk inhibitor for treating cancer |
| DK3512536T3 (da) | 2016-09-15 | 2020-11-23 | Leidos Inc | Pd-1-peptidinhibitorer |
| CN107383174B (zh) | 2017-08-21 | 2019-01-18 | 生工生物工程（上海）股份有限公司 | 一种能与pd-1特异性结合的肿瘤抑制肽及其用途 |
-
2017
- 2017-09-15 DK DK17778394.1T patent/DK3512536T3/da active
- 2017-09-15 WO PCT/US2017/051697 patent/WO2018053218A1/en not_active Ceased
- 2017-09-15 US US15/705,333 patent/US10098950B2/en active Active
- 2017-09-15 CA CA3036251A patent/CA3036251A1/en active Pending
- 2017-09-15 AU AU2017325866A patent/AU2017325866B2/en active Active
- 2017-09-15 JP JP2019515467A patent/JP6928083B2/ja active Active
- 2017-09-15 EP EP20204314.7A patent/EP3795167B1/en active Active
- 2017-09-15 EP EP17778394.1A patent/EP3512536B1/en active Active
- 2017-09-15 DK DK20204314.7T patent/DK3795167T3/da active
-
2018
- 2018-03-01 US US15/908,861 patent/US10799581B2/en active Active
-
2020
- 2020-09-21 US US17/026,447 patent/US20210000948A1/en not_active Abandoned
-
2023
- 2023-11-08 US US18/388,036 patent/US20240075131A1/en not_active Abandoned